Temedica develops various digital therapy companions and links these apps with its insights platform Permea. the Munich startup Temedica combines data from a variety of sources, including registry data, sales data for medically relevant products, and insurance data. In this way, Temedica aims to provide a comprehensive view of patients' care reality and improve individualized, patient-centered care.
The data collected in this way will not only benefit doctors and clinics, but also patients themselves. Patient companion apps will provide them with a personalized understanding of their illness and information about its connection to their lifestyle. In this way, Temedica aims to enable patients to actively influence their illness. The startup promises the highest possible level of privacy and data protection.
Gloria Seibert, Founder & CEO of Temedica, explains:
"Temedica's vision is to make a groundbreaking contribution to the development of personalized medicine by linking health-relevant data to create new, evidence-based insights. We believe that large data sets and entirely new data types play a key role in this, such as patient-generated data from large populations outside of traditional clinical trials. These enable entirely new knowledge and understanding of diseases and their actual progression. I am delighted that our investors share this vision and are committed to supporting and accompanying us in the further expansion of the Temedica ecosystem."
Investors believe in Temedica's vision
The expansion of the financing round is led by existing investors MIG Capital and a Munich-based family office. The investors are supporting the Munich-based startup with an additional 25 million euros. Series B round completed in early 2020In the round, which brought the startup €17 million, MIG Fonds, Santo Venture Capital, and Salvia participated as lead investors. Existing shareholders such as Bernd Wendeln and G+J Digital Ventures also reinvested.
Boris Bernstein, partner of MIG Capital, emphasizes:
"Temedica operates in a massively growing and highly attractive market. The newly developed real-world insights platform Permea offers life science companies a deep understanding of patients and their care in the real world – outside of clinical trials. Access to this unique 360-degree understanding of the reality of care has the potential to revolutionize our healthcare system as we know it. The employees at Temedica are highly motivated and goal-oriented, and we are very excited to work with the team and continue our journey together."
